Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shionogi; Shire
- 20 Sep 2017 Shionogi will evaluate the full data and will investigate plans for disclosure of detailed data, as reported in a Shionogi media release.
- 20 Sep 2017 Results published in the Shionogi Media Release
- 20 Sep 2017 Primary endpoint has been met. (Change in the baseline of the ADHD evaluation scale in the INTUNIV group), as reported in a Shionogi media release.